Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Acute Myelogenous Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (1944
)
Acute Lymphocytic Leukemia (389
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (1944
)
Acute Lymphocytic Leukemia (389
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(902)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
PLD-102
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
PLD-102
Sensitive
:
D
AACR 2023 - 2wk
PLD-102
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
PLD-102
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
U2AF1 mutation
Acute Myelogenous Leukemia
U2AF1 mutation
Acute Myelogenous Leukemia
HPB-092
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
HPB-092
Sensitive
:
D
AACR 2023 - 2wk
HPB-092
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
HPB-092
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
SF3B1 mutation
Acute Myelogenous Leukemia
SF3B1 mutation
Acute Myelogenous Leukemia
HPB-092
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
HPB-092
Sensitive
:
D
AACR 2023 - 2wk
HPB-092
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
HPB-092
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
CD33 positive
Acute Myelogenous Leukemia
CD33 positive
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: A1 - Approval
olutasidenib
Sensitive
:
A1
olutasidenib
Sensitive: A1 - Approval
olutasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
Chr t(15;17)
Acute Promyelocytic Leukemia
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
PML-RARA fusion
Acute Promyelocytic Leukemia
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine
Sensitive: A1 - Approval
azacitidine
Sensitive
:
A1
azacitidine
Sensitive: A1 - Approval
azacitidine
Sensitive
:
A1
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
idarubicin hydrochloride
Sensitive: A1 - Approval
idarubicin hydrochloride
Sensitive
:
A1
idarubicin hydrochloride
Sensitive: A1 - Approval
idarubicin hydrochloride
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
RUNX1-RUNX1T1 fusion
Acute Myelogenous Leukemia
RUNX1-RUNX1T1 fusion
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
CBFB-MYH11 fusion
Acute Myelogenous Leukemia
CBFB-MYH11 fusion
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive
:
A2
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Promyelocytic Leukemia
No biomarker
Acute Promyelocytic Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Promyelocytic Leukemia
No biomarker
Acute Promyelocytic Leukemia
cytarabine + daunorubicin
Sensitive: A2 - Guideline
cytarabine + daunorubicin
Sensitive
:
A2
cytarabine + daunorubicin
Sensitive: A2 - Guideline
cytarabine + daunorubicin
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login